Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. develops precision oncology therapies for cancers driven by the RAS/MAPK pathway. News on ERAS commonly centers on its RAS-targeting pipeline, including ERAS-0015, an investigational oral pan-RAS molecular glue evaluated in RAS-mutant solid tumors, and ERAS-4001, an oral pan-KRAS inhibitor for KRAS-mutant solid tumors.
Company updates frequently cover Phase 1 clinical data, dose-escalation results, trial collaborations and supply agreements, intellectual-property protection, development rights, public offering activity, financial results, and healthcare conference presentations. Recurring cancer settings in company disclosures include non-small cell lung cancer, pancreatic adenocarcinoma, colorectal cancer, and other RAS-mutant solid tumors.
Erasca (Nasdaq: ERAS) reported first quarter 2026 results and RAS-franchise progress. ERAS-0015 showed robust preliminary monotherapy responses in KRAS G12X NSCLC and PDAC with generally low-grade AEs, and expansion and combination cohorts began ahead of prior guidance. ERAS-4001 advanced in Phase 1 with US patent protection to June 2043.
Clinical collaborations were signed with Merck to combine ERAS-0015 with KEYTRUDA and with Tango for combination with vopimetostat. Cash, cash equivalents, and marketable securities totaled $408.5 million, including proceeds from a $258.8 million January 2026 offering, funding operations into H2 2028. Q1 2026 net loss was $183.4 million, driven by a $150.0 million in-process R&D charge related to expanding ERAS-0015 license territory to worldwide.
Erasca (Nasdaq: ERAS) announced a clinical trial collaboration and supply agreement with Merck to evaluate ERAS-0015, a pan-RAS molecular glue, with KEYTRUDA (pembrolizumab) in RAS-mutant solid tumors.
The AURORAS-1 proof-of-concept study is sponsored by Erasca, with Merck supplying pembrolizumab at no cost.
Erasca (Nasdaq: ERAS) will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas. Management will take part in a fireside chat on Wednesday, May 13, 2026 at 3:00 pm PT and hold one-on-one investor meetings.
A live audio webcast will be available at Erasca.com/events, with an archived replay accessible for 30 days after the webcast.
Erasca (Nasdaq: ERAS) announced positive preliminary Phase 1 dose escalation data for pan-RAS molecular glue ERAS-0015 in RAS-mutant solid tumors on April 27, 2026. Key points: PAD 16–32 mg QD; selected RDEs 24 mg and 32 mg QD; robust uORRs in KRAS G12X NSCLC (62% 2L+, 75% post-ICI/platinum) and PDAC (40% 2L); favorable safety with no DLTs as of DCO; PK dose-dependent to MAD 40 mg QD. Monotherapy expansion and combo cohorts data expected H1 2027.
Erasca (Nasdaq: ERAS) will host a conference call and live webcast on April 27, 2026 at 4:30 PM ET to discuss preliminary Phase 1 dose-escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.
Investors can join via webcast at Erasca.com/events or by phone (1-877-407-3982 U.S./Canada; 1-201-493-6780 international).
Erasca (Nasdaq: ERAS) reported Q4 and full-year 2025 results and business updates on March 12, 2026. The company highlighted promising early Phase 1 activity for ERAS-0015, planned H1 2026 monotherapy data for ERAS-0015 and H2 2026 data for ERAS-4001, a $258.8M upsized financing, and $341.8M cash at 12/31/2025.
Management expects pro forma cash of $434M to fund operations into H2 2028; issued U.S. composition patents protect ERAS-0015 and ERAS-4001 through 2043.
Erasca (Nasdaq: ERAS) exercised its option to expand the ERAS-0015 license with Joyo to include China, Hong Kong, and Macau, securing worldwide rights for the pan-RAS molecular glue. Erasca will make a one-time payment tied to Joyo’s development stage and plans unified global development.
ERAS-0015 has shown promising early clinical activity across multiple tumor types and RAS mutations at low doses; initial Phase 1 monotherapy data are expected in H1 2026.
Erasca (Nasdaq: ERAS) and Tango Therapeutics announced a clinical collaboration and supply agreement to evaluate Erasca’s pan-RAS molecular glue ERAS-0015 combined with Tango’s PRMT5 inhibitor vopimetostat in a Phase 1/2 trial for MTAP-deleted pancreatic cancer and MTAP-deleted RAS-mutant NSCLC.
Tango will sponsor the trial; Erasca will supply ERAS-0015 at no cost. The collaboration is mutually non-exclusive and each company retains commercial rights to its compound.
Erasca (Nasdaq: ERAS) announced issuance of U.S. Patent No. 12,552,813 covering the composition of matter for its pan-KRAS inhibitor ERAS-4001, with protection until at least June 2043. The patent broadens Erasca’s RAS IP portfolio and supports its ERAS-4001 program; additional patents are pending. Erasca expects Phase 1 monotherapy data for ERAS-0015 in 1H 2026 and for ERAS-4001 in 2H 2026.
Erasca (Nasdaq: ERAS) announced management will present and hold one-on-one investor meetings at two February 2026 conferences: Guggenheim Emerging Outlook: Biotech Summit (Feb 11-12) and Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 25-26).
Fireside chat times: Feb 12 at 1:00 PM ET (Guggenheim) and Feb 26 at 11:20 AM ET (Oppenheimer). Live audio webcasts and archived replays will be available at Erasca.com/events for 30 days following each webcast.